Sinotherapeutics (SH:688247) Xin Lang Cai Jing·2026-01-05 01:40Group 1 - The core viewpoint of the news is that Xuantai Pharmaceutical has experienced a decline in stock performance and financial metrics, indicating potential challenges in its business operations [1][2]. - As of December 31, Xuantai Pharmaceutical's stock fell by 0.21%, with a trading volume of 16.61 million yuan. The net financing buy was -1.30 million yuan, with a total financing and securities balance of 119 million yuan [1]. - The company’s financing balance of 119 million yuan accounts for 2.71% of its market capitalization, which is above the 90th percentile level over the past year, indicating a high level of financing activity [1]. - The company’s revenue composition includes 69.85% from product sales, 9.38% from CRO services, and smaller contributions from other services [1]. Group 2 - As of September 30, the number of shareholders for Xuantai Pharmaceutical was 7,759, a decrease of 3.25% from the previous period, while the average circulating shares per person increased by 229.25% to 58,427 shares [2]. - For the period from January to September 2025, Xuantai Pharmaceutical reported a revenue of 331 million yuan, a year-on-year decrease of 8.59%, and a net profit attributable to shareholders of 63.46 million yuan, down 31.45% year-on-year [2]. - The company has distributed a total of 85.59 million yuan in dividends since its A-share listing [3].